Stoke Therapeutics
Stoke Therapeutics' revenue rose 404.5% to $184 million in fiscal 2025. Its operating margin was −11.2%, up from −277.3% a year earlier. Free cash flow was $45 million. The diluted share count rose 9.7%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Stoke Therapeutics does
Stoke Therapeutics is a late-stage clinical company that develops medicines for severe genetic diseases. It has no approved product. Its approach, which it calls TANGO, uses antisense oligonucleotides (short pieces of genetic material) to raise the amount of a protein the body makes too little of. This targets diseases caused by having only about half the normal protein level, starting with diseases of the brain and the eye.
Its lead candidate, zorevunersen, is being tested for Dravet syndrome, a severe genetic epilepsy that starts in the first year of life and causes frequent seizures and developmental delays. The company says no approved medicine treats the underlying causes of Dravet. A global Phase 3 trial began in 2025, following earlier studies in the United States and the United Kingdom. A second candidate targets a genetic eye disease called autosomal dominant optic atrophy.
Stoke has no product revenue. It works with Biogen, which has rights to the Dravet candidate outside the United States, Canada and Mexico, and may receive milestone and royalty payments from it.
Its biggest risks, as it describes them
- Its business depends on zorevunersen and its other candidates succeeding in trials and winning approval.
- Early results may not hold up in later trials, and regulators may not approve its medicines.
- Diseases that few people have are hard to enroll in trials, which can cause delays.
- It relies on Biogen and on outside firms for trials, supply and parts of its work.
- It has a history of losses and may need to raise more money.
Income statement
Stoke Therapeutics lost money in fiscal 2025: a net loss of $7 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 220 | 230 | 201 | 217 | 285 |
| Debt incl. finance leases | — | — | — | — | — |
| Net debt (negative means net cash) | — | — | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | — |
| Interest coverage | — | — | −2,342.3x | −3,898.9x | −2,287.8x |
| Current ratio | 13.4x | 7.8x | 7.0x | 5.8x | 5.3x |
| Quick ratio | 13.4x | 7.8x | 7.0x | 5.8x | 5.3x |
Cash flow
Projections
Project Stoke Therapeutics' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 14, 2025 and November 13, 2026, no insider bought Stoke Therapeutics shares on the open market, and 8 insiders sold $8.7 million, $7.2 million of it under trading plans set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 1, 2026 | Barry TichoChief Medical Officer | Sold plan | 5,545 | $30.67 | $170,058 | Form 4 |
| Aug 18, 2026 | Edward M. MD KayeDirector | Sold | 12,567 | $32.03 | $402,563 | Form 4 |
| Aug 18, 2026 | Barry TichoChief Medical Officer | Sold | 4,767 | $32.03 | $152,703 | Form 4 |
| Aug 18, 2026 | Jonathan AllanGeneral Counsel & Corp Sec | Sold | 2,861 | $32.03 | $91,647 | Form 4 |
| Aug 3, 2026 | Barry TichoChief Medical Officer | Sold plan | 7,176 | $29.04 | $208,380 | Form 4 |
| Jul 1, 2026 | Barry TichoChief Medical Officer | Sold plan | 7,228 | $32.66 | $236,102 | Form 4 |
| Jun 16, 2026 | Jonathan AllanGeneral Counsel & Corp Sec | Sold plan | 1,457 | $29.95 | $43,637 | Form 4 |
| Jun 1, 2026 | Barry TichoChief Medical Officer | Sold plan | 1,795 | $30.58 | $54,891 | Form 4 |
| May 1, 2026 | Barry TichoChief Medical Officer | Sold plan | 2,243 | $32.79 | $73,548 | Form 4 |
| Apr 1, 2026 | Barry TichoChief Medical Officer | Sold plan | 1,838 | $32.66 | $60,029 | Form 4 |
| Mar 20, 2026 | Jonathan AllanGeneral Counsel & Corp Sec | Sold plan | 9,293 | $33.69 | $313,079 | Form 4 |
| Mar 19, 2026 | Barry TichoChief Medical Officer | Sold plan | 1,461 | $29.99 | $43,815 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | −970.9% | 78.2% | 428.9% |
| Altman Z'' | −1.38 | 1.91 | 5.29 |
| Accruals ratio | −9.8% | −0.8% | −15.2% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Pass |
| Return on assets rose | Pass | Pass | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Fail | Fail | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | Fail | Pass | Pass |
| F-score | — | — | — |
Compare
Put Stoke Therapeutics side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Stoke Therapeutics | FY25 | 404.5% | −11.2% | 24.4% | — | — | — | |
| Rhythm Pharmaceuticals | FY25 | 45.8% | −101.2% | −61.5% | — | — | 6 | Compare |
| Syndax Pharmaceuticals | FY25 | 627.8% | −158.4% | −187.5% | — | — | — | Compare |
| Liquidia | FY25 | 1,031.2% | −32.5% | −25.3% | — | — | — | Compare |
| IDEAYA Biosciences | FY25 | 3,024.4% | −72.8% | −33.6% | — | — | — | Compare |
8 years of figures
| Fiscal year | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | 12 | 9 | 37 | 184 |
| Revenue growth | — | — | — | — | — | −29.2% | 316.3% | 404.5% |
| Gross profit | — | — | — | — | — | — | — | — |
| Research and development | 8 | 24 | 32 | 54 | 78 | 82 | 89 | 138 |
| Operating income | −13 | −36 | −53 | −86 | −104 | −115 | −101 | −21 |
| Net income | −12 | −32 | −52 | −86 | −101 | −105 | −89 | −7 |
| Diluted EPS (US$) | −17.65 | −1.80 | −1.56 | −2.34 | −2.60 | −2.38 | −1.65 | −0.12 |
| Diluted shares (millions) | 1 | 18 | 34 | 37 | 39 | 44 | 54 | 59 |
| Cash flow | ||||||||
| Cash from operations | −11 | −31 | −42 | −67 | −32 | −81 | −87 | 46 |
| Capital expenditure | 1 | 2 | 1 | 1 | 4 | 2 | 0 | 1 |
| Free cash flow | −12 | −33 | −43 | −68 | −36 | −83 | −87 | 45 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 0 | 2 | 6 | 16 | 23 | 25 | 28 | 32 |
| Balance sheet at fiscal year end | ||||||||
| Cash and short-term investments | 105 | 222 | 287 | 220 | 230 | 201 | 217 | 285 |
| Debt incl. finance leases | — | — | — | — | — | — | — | — |
| Total assets | 108 | 229 | 298 | 239 | 256 | 228 | 272 | 418 |
| Total liabilities | 2 | 4 | 12 | 21 | 71 | 69 | 42 | 66 |
| Shareholders' equity | 105 | 224 | 286 | 218 | 185 | 160 | 229 | 352 |
| Margins and ratios | ||||||||
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | −841.2% | −1,307.2% | −277.3% | −11.2% |
| Net margin | — | — | — | — | −814.7% | −1,192.5% | −243.4% | −3.7% |
| Free cash flow margin | — | — | — | — | −288.8% | −941.7% | −238.2% | 24.4% |
| Rule of 40 (growth + FCF margin) | — | — | — | — | — | −970.9% | 78.2% | 428.9% |
| Return on capital | — | — | — | — | — | — | — | — |
| Return on equity | — | −19.6% | −20.5% | −34.1% | −50.2% | −60.8% | −45.8% | −2.4% |
| Return on assets | — | −19.2% | −19.8% | −32.0% | −40.8% | −43.2% | −35.6% | −2.0% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — |